90P HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): A phase II trial

The combination treatment using sintilimab (a PD-1 antibody) and bevacizumab (bev) biosimilar demonstrated excellent efficacy and safety in ORIENT-32 study and HAIC performed impressive tumor response in researches. We assessed the efficacy and safety of the combination therapy as first-line treatment for initial unresectable HCC.